New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2013
08:03 EDTCLSNCelsion reports clinical data from Phase 1 trials of ThermoDox plus hyperthermia
ThermoDox in combination with mild hyperthermia was evaluated in these patients in up to six cycles. Both studies employed an open label 3+3 dose escalation study design to determine the Maximum Tolerated Dose, evaluate safety and determine early effects of ThermoDox® in combination with mild hyperthermia. A local response rate of over 60% was reported in 14 of the 23 evaluable patients with 5 complete responses and 9 partial responses. Based on the results from these two Phase I studies, Celsion is currently enrolling up to 20 patients in an open label Phase 2 study at 5 US clinical sites.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
08:03 EDTCLSNCelsion announces data supporting development of ThermoDox
Celsion announced that data supporting the development of ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound were presented at the International Symposium on Therapeutic Ultrasound. Mark Dewhirst, D.V.M., Ph.D. presented data demonstrating the potential of ThermoDox plus HIFU to maximize drug delivery to the targeted tumor site. Celsion is exploring the potential of ThermoDox in combination with HIFU as a non-invasive treatment for a variety of cancers, including pancreatic cancer, Glioblastoma Multiforme, metastatic liver cancer, and breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use